Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Cash & Equivalents (2016 - 2025)

Ani Pharmaceuticals' Cash & Equivalents history spans 16 years, with the latest figure at $285.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 97.14% year-over-year to $285.6 million; the TTM value through Dec 2025 reached $285.6 million, up 97.14%, while the annual FY2025 figure was $285.6 million, 97.14% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $285.6 million at Ani Pharmaceuticals, up from $262.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $285.6 million in Q4 2025 and bottomed at $15.3 million in Q3 2021.
  • The 5-year median for Cash & Equivalents is $144.9 million (2024), against an average of $136.4 million.
  • The largest annual shift saw Cash & Equivalents surged 1175.43% in 2021 before it crashed 51.92% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $100.3 million in 2021, then crashed by 51.92% to $48.2 million in 2022, then skyrocketed by 358.49% to $221.1 million in 2023, then plummeted by 34.49% to $144.9 million in 2024, then skyrocketed by 97.14% to $285.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Cash & Equivalents are $285.6 million (Q4 2025), $262.6 million (Q3 2025), and $217.8 million (Q2 2025).